


Constraint Date Forecast or Loss of Exclusivity date

The **Constraint Date Forecast (formerly the Newport Constraint Date)** predicts when a product is expected to lose exclusivity in over 35 global markets. This date is calculated by an algorithm considering different types of protection such as patents, market/data exclusivities, granted Supplementary Protection Certificates (SPCs) and pediatric protections for a specific product in a given country. **Please note** that the CDF should be used as a guideline and not be taken as a definitive date.


Example

Find the Constraint Date Forecast (CDF) for a specific product and understand when that product will “go generic” in over 35 global markets.

1. Type the name of the product in the **Quick Search bar** and select from the list.



2. In the **Unexpired Constraint Date Forecast and Exclusivities** table on the **Product Key Insights** page you will find Constraint Dates Forecast and rationale behind them.



3. **Constraint Date Forecast** table displays all countries where CDF is available.

cariprazine hydrochloride

PRODUCT KEY INSIGHTS | API MANUFACTURERS | REGULATORY FILINGS | APPROVALS | **CONSTRAINT DATE FORECAST & EXCLUSIVITIES** | PATENTS & SPCS | US PATENT CHALLENGES | DEALS | COMPETITIVE INSIGHTS | R&D | SCIENTIFIC

LAUNCHES & PACK PRICES | US MARKET SHARE | LATAM MARKET SHARE

Filters Country/Territory

Constraint Date Forecast & Exclusivities Customize Columns Export

Showing 1-10 of 36

COUNTRY/TERRITORY	CONSTRAINT DATE	CONSTRAINT DATE RATIONALE	EXCLUSIVITIES
USA	In Litigation	No data	cariprazine hydrochloride has unexpired 1 NEW INDICATION (24-May-2022) exclusivity in the Orange Book.
Canada	21-May-2024	It is based on the expiry date of a Product Patent	No data
Belgium	17-Jul-2027	It is based on the expiry date of Data + Marketing Exclusivity	Data + Marketing exclusivity in Belgium expires on 17-Jul-2027, 8+2 years from the notification of first marketing authorization in EEA on 17-Jul-2017.

Customize your table by displaying or hiding columns, and sorting.

The selection below shows when generic launches are expected for cariprazine hydrochloride in several countries and rationale for the CDF.

cariprazine hydrochloride

PRODUCT KEY INSIGHTS | API MANUFACTURERS | REGULATORY FILINGS | APPROVALS | **CONSTRAINT DATE FORECAST & EXCLUSIVITIES** | PATENTS & SPCS | US PATENT CHALLENGES | DEALS | COMPETITIVE INSIGHTS | R&D | SCIENTIFIC

LAUNCHES & PACK PRICES | US MARKET SHARE | LATAM MARKET SHARE

Filters Country/Territory

Constraint Date Forecast & Exclusivities Customize Columns Export

Showing 1-10 of 36

COUNTRY/TERRITORY	CONSTRAINT DATE	CONSTRAINT DATE RATIONALE	EXCLUSIVITIES
USA	In Litigation	No data	cariprazine hydrochloride has unexpired 1 NEW INDICATION (24-May-2022) exclusivity in the Orange Book.
Canada	21-May-2024	It is based on the expiry date of a Product Patent	No data
Belgium	17-Jul-2027	It is based on the expiry date of Data + Marketing Exclusivity	Data + Marketing exclusivity in Belgium expires on 17-Jul-2027, 8+2 years from the notification of first marketing authorization in EEA on 17-Jul-2017.

Under Exclusivities see the rationale for the CDF.

To find details on potential extension and patents worldwide, please go to the next tab 'Patents and SPCs'.
For more information contact Customer Service at [LS Product Support](#)